Quest Partners LLC Has $90,000 Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Quest Partners LLC boosted its position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 3,283.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 3,688 shares of the biotechnology company’s stock after acquiring an additional 3,579 shares during the period. Quest Partners LLC’s holdings in Arcturus Therapeutics were worth $90,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the business. Russell Investments Group Ltd. purchased a new stake in Arcturus Therapeutics in the 1st quarter valued at $40,000. CANADA LIFE ASSURANCE Co grew its holdings in Arcturus Therapeutics by 10.5% during the first quarter. CANADA LIFE ASSURANCE Co now owns 4,492 shares of the biotechnology company’s stock valued at $152,000 after purchasing an additional 428 shares during the period. Public Employees Retirement System of Ohio raised its stake in Arcturus Therapeutics by 63.8% in the 1st quarter. Public Employees Retirement System of Ohio now owns 4,620 shares of the biotechnology company’s stock valued at $156,000 after acquiring an additional 1,800 shares during the period. China Universal Asset Management Co. Ltd. raised its position in shares of Arcturus Therapeutics by 66.8% in the first quarter. China Universal Asset Management Co. Ltd. now owns 5,153 shares of the biotechnology company’s stock valued at $174,000 after purchasing an additional 2,064 shares during the period. Finally, Caxton Associates LP bought a new stake in Arcturus Therapeutics during the 1st quarter valued at $202,000. Institutional investors and hedge funds own 94.54% of the company’s stock.

Wall Street Analysts Forecast Growth

ARCT has been the subject of several research analyst reports. William Blair reissued an “outperform” rating on shares of Arcturus Therapeutics in a research note on Thursday, May 23rd. HC Wainwright lifted their target price on shares of Arcturus Therapeutics from $60.00 to $63.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. Leerink Partners initiated coverage on Arcturus Therapeutics in a research note on Monday, August 12th. They issued an “outperform” rating and a $70.00 price target on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arcturus Therapeutics in a report on Monday, September 9th. Finally, Leerink Partnrs upgraded shares of Arcturus Therapeutics to a “strong-buy” rating in a report on Monday, August 12th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $71.40.

Arcturus Therapeutics Price Performance

Shares of ARCT opened at $21.01 on Wednesday. Arcturus Therapeutics Holdings Inc. has a 1 year low of $17.52 and a 1 year high of $45.00. The business’s 50 day simple moving average is $21.29 and its 200-day simple moving average is $27.42. The stock has a market capitalization of $565.84 million, a price-to-earnings ratio of -5.37 and a beta of 2.60.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.85) by $1.21. The business had revenue of $49.86 million during the quarter, compared to the consensus estimate of $21.00 million. Arcturus Therapeutics had a negative net margin of 41.21% and a negative return on equity of 25.47%. During the same quarter last year, the firm earned ($1.98) earnings per share. On average, sell-side analysts expect that Arcturus Therapeutics Holdings Inc. will post -2.6 earnings per share for the current year.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.